Cargando…

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas

BACKGROUND: Epigenetic, genetic, and molecular studies have identified several diagnostic and prognostic markers in diffuse gliomas. Their importance for evaluating WHO grade II gliomas has yet to be specifically delineated. METHODS: We analyzed markers, including IDH mutation(IDHmut), 1p19q codelet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leeper, Heather E., Caron, Alissa A., Decker, Paul A., Jenkins, Robert B., Lachance, Daniel H., Giannini, Caterina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745799/ https://www.ncbi.nlm.nih.gov/pubmed/26210286

Ejemplares similares

Frequency of false-positive FISH 1p/19q codeletion in adult diffuse astrocytic gliomas
por: Ball, Matthew K, et al.
Publicado: (2020)

Radiomics-Based Method for Predicting the Glioma Subtype as Defined by Tumor Grade, IDH Mutation, and 1p/19q Codeletion
por: Li, Yingping, et al.
Publicado: (2022)

Primary Leptomeningeal Oligodendroglioma, IDH-Mutant, 1p/19q-Codeleted
por: Ballester, Leomar Y., et al.
Publicado: (2018)

Effects of 1p/19q Codeletion on Immune Phenotype in Low Grade Glioma
por: Lv, Lei, et al.
Publicado: (2021)

Proteomics separates adult-type diffuse high-grade gliomas in metabolic subgroups independent of 1p/19q codeletion and across IDH mutational status
por: Bader, Jakob Maximilian, et al.
Publicado: (2022)

ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma
por: Babikir, Husam, et al.
Publicado: (2021)

T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology
por: Foltyn, Martha, et al.
Publicado: (2020)

Mass spectrometry-based assay for the molecular diagnosis of glioma: concomitant detection of chromosome 1p/19q codeletion, and IDH1, IDH2, and TERT mutation status
por: Pesenti, Chiara, et al.
Publicado: (2017)

Case report: Spinal drop metastasis of IDH-mutant, 1p/19q-codeleted oligodendroglioma
por: Karaman, Ahmet Kursat, et al.
Publicado: (2022)

The role of DSC MR perfusion in predicting IDH mutation and 1p19q codeletion status in gliomas: meta-analysis and technical considerations
por: Siakallis, Loizos, et al.
Publicado: (2023)

Efficient diagnosis of IDH-mutant gliomas: 1p/19qNET assesses 1p/19q codeletion status using weakly-supervised learning
por: Kim, Gi Jeong, et al.
Publicado: (2023)

A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients
por: Zhu, Zheng, et al.
Publicado: (2020)

The T2-FLAIR Mismatch Sign as an Imaging Indicator of IDH-Mutant, 1p/19q Non-Codeleted Lower Grade Gliomas: A Systematic Review and Diagnostic Accuracy Meta-Analysis
por: Adamou, Antonis, et al.
Publicado: (2021)

ATRX immunostaining predicts IDH and H3F3A status in gliomas
por: Ebrahimi, Azadeh, et al.
Publicado: (2016)

Overexpression of PSAT1 Gene is a Favorable Prognostic Marker in Lower-Grade Gliomas and Predicts a Favorable Outcome in Patients with IDH1 Mutations and Chromosome 1p19q Codeletion
por: Huang, Shang-Pen, et al.
Publicado: (2019)

How I treat anaplastic glioma without 1p/19q codeletion
por: Berghoff, Anna, et al.
Publicado: (2019)

Novel, clinically relevant genomic patterns identified by comprehensive genomic profiling in ATRX-deficient IDH-wildtype adult high-grade gliomas
por: Bedics, Gábor, et al.
Publicado: (2023)

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
por: Jiao, Yuchen, et al.
Publicado: (2012)

Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas
por: Cai, Jinquan, et al.
Publicado: (2016)

Immunohistochemical Expression of IDH1, ATRX, Ki67, GFAP, and Prognosis in Indonesian Glioma Patients
por: Priambada, Dody, et al.
Publicado: (2023)

Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1(R132H) mutation and may predict better prognosis among glioblastomas without the IDH1 mutation and ATRX loss
por: Cai, Hong-Qing, et al.
Publicado: (2018)

Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p/19q codeletion status in newly diagnosed malignant gliomas
por: Suzuki, Kenta, et al.
Publicado: (2021)

Case report: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, associated with a germline mutation in PMS2
por: Merchant, Mythili, et al.
Publicado: (2022)

Bone metastases from a 1p/19q codeleted and IDH1-mutant anaplastic oligodendroglioma: a case report
por: Burgy, Mickaël, et al.
Publicado: (2019)

T(2)-FLAIR Mismatch Sign Is Caused by Long T(1) and T(2) of IDH-mutant, 1p19q Non-codeleted Astrocytoma
por: Kinoshita, Manabu, et al.
Publicado: (2020)

A Multigene Signature Associated with Progression-Free Survival after Treatment for IDH Mutant and 1p/19q Codeleted Oligodendrogliomas
por: Gilhodes, Julia, et al.
Publicado: (2023)

FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas
por: Sharaf, Radwa, et al.
Publicado: (2021)

MRI-based classification of IDH mutation and 1p/19q codeletion status of gliomas using a 2.5D hybrid multi-task convolutional neural network
por: Chakrabarty, Satrajit, et al.
Publicado: (2023)

The Role of ATRX in Glioma Biology
por: Nandakumar, Pravanya, et al.
Publicado: (2017)

Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study
por: Habiba, Umma, et al.
Publicado: (2021)

Report of multiple high-grade gliomas in two patients with shared retained ATRX, wild-type IDH, losses of CDKN2A genes and alterations in the PTEN–PI3K axis
por: Khatchadourian, Christopher, et al.
Publicado: (2023)

Erratum to: FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas
por: Sharaf, Radwa, et al.
Publicado: (2021)

Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas
por: Filipski, Katharina, et al.
Publicado: (2019)

Transcriptional Characteristics of IDH-Wild Type Glioma Subgroups Highlight the Biological Processes Underlying Heterogeneity of IDH-Wild Type WHO Grade IV Gliomas
por: Chang, Yu-Zhou, et al.
Publicado: (2020)

Significance of TERT and ATRX mutations in glioma
por: Liu, Jiayu, et al.
Publicado: (2019)

Radiological assessment schedule for 1p/19q-codeleted gliomas during the surveillance period using parametric modeling
por: Kang, Ho, et al.
Publicado: (2021)

Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter mutation that is typical of their adult counterparts
por: Lee, Julieann, et al.
Publicado: (2018)

Updates on the WHO diagnosis of IDH-mutant glioma
por: Reuss, David.E.
Publicado: (2023)

The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas
por: Grandin, Nathalie, et al.
Publicado: (2019)

Capitalizing on ATRX loss in glioma via PARP inhibition: Comment on “Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity” by Garbarino et al.
por: Zalenski, Abigail A, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vg31b2pq1ojhmrf0sugrvu7t5t